Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients

Overview

This research study is studying how healthcare worker recipients react after receiving vaccinations for COVID-19. The objective of the study is to evaluate the immune response to COVID-19 vaccination. The immunity will be evaluated over time by measuring serum semi-quantitative SARS-Co-V2 IgG from blood specimens and analyzing vaccine reaction data. SARS-CoV-2 is the name for the virus responsible for COVID-19 infections. IgG, immunoglobulin G, is an antibody found in the blood that protects against bacterial and viral infections. Study subjects will also be asked to report physical reactions they may have experienced related to vaccinations.

Full Title of Study: “Post Vaccination Antibody Assays and Reactions in Hospital Employees and Medical Staff: An Analysis of Antibody Response Over Time”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 2022

Detailed Description

As some of the first recipients of SARS-CoV-2 vaccines under emergency authorization use, healthcare workers represent a diverse subpopulation, that are now moving through the immune response to the Pfizer and Moderna mRNA vaccines. As individual responses may vary, this provides an opportunity to evaluate levels of IgG response in relation to age, gender, comorbidities and other factors that may influence immunity. We recognize that, though this is only part of the immune response that may be protective for severe COVID-19 disease, it is a first step in understanding the level and durability of post vaccination SARS-CoV-2 antibodies. This small, pilot study will evaluate the immune response over time by measuring serum semi-quantitative SARS-CoV-2 IgG from healthcare vaccinees at various timepoints. A high-level review of reactions related to the vaccinations will be performed with the same population of healthcare workers.

Interventions

  • Drug: COVID-19 vaccine
    • Two-dose COVID-19 vaccine

Clinical Trial Outcome Measures

Primary Measures

  • Change in SARS-CoV-2 IgG Titer Over Time
    • Time Frame: 8 weeks (± 5 days) post-vaccination regimen completion; 24 weeks (± 5 days) post-vaccination regimen completion; and 52 weeks (± 5 days) post-vaccination regimen completion
    • Semi-quantitative SARS-CoV-2 IgG titer

Secondary Measures

  • Occurrence of post-vaccine reactions
    • Time Frame: Within 3 days after vaccine injections
    • Subjective reporting of occurrence of post-vaccination reactions including anaphylactic reactions (such as difficulty breathing, swelling of face and throat, fast heartbeat, bad rash all over body, and dizziness and weakness); injection site pain; injection site swelling/hardness; injection site redness; tiredness; headache; muscle pain; chills; join pain; fever; nausea; feeling unwell; and/or swollen lymph nodes
  • Severity of post-vaccine reactions
    • Time Frame: Within 3 days after vaccine injections
    • Subjective reporting of severity of post-vaccine reactions (none, mild, moderate, or severe)

Participating in This Clinical Trial

Inclusion Criteria

  • Signed informed consent for study – Current employee or active member of the medical staff of Huntington Hospital, Pasadena, CA, (must have valid hospital identification) – Must have completed vaccination regimen (two doses if required) no more than 8 weeks ± 5 days before enrollment – Must have completed, valid vaccination card, if vaccinations received at a center other than Huntington Hospital – Able to read English, sign consent form and complete on-line surveys Exclusion Criteria:

  • Huntington Hospital employees on leave of absence – Anyone not able/willing to provide blood specimens and respond to surveys for the 52-week study period

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Huntington Memorial Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Kimberly Shriner, MD, Principal Investigator, Huntington Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.